A New Option for Kidney Health The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab-cwvz) for the treatment of adults with immunoglobulin A nephropathy (IgAN). This milestone marks Ultomiris as the first and only C5 complement inhibitor indicated to reduce proteinuria in patients with this progressive kidney disease. Understanding the…